Investment Analysts’ Weekly Ratings Changes for ABIOMED (ABMD)

ABIOMED (NASDAQ: ABMD) recently received a number of ratings updates from brokerages and research firms:

  • 1/2/2019 – ABIOMED had its price target lowered by analysts at Morgan Stanley from $496.00 to $461.00. They now have an “overweight” rating on the stock.
  • 1/2/2019 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Abiomed outperformed the industry in a year’s time. The company continues to gain from its flagship Impella which saw a solid performance in the United States in recent times. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan also shot up. A raised guidance for fiscal 2019 is indicative of brighter prospects ahead. Considerable expansion in the operating margin buoys optimism. Surging R&D expenses show increasing focus on innovation. Abiomed’s balance sheet remains debt-free. On the flip side, contraction in the company’s gross margin is worrisome. Intense competition in the industry is likely to mar prospects over the long haul. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.”
  • 12/31/2018 – ABIOMED had its “buy” rating reaffirmed by analysts at Zacks Investment Research. They now have a $332.00 price target on the stock. According to Zacks, “Abiomed outperformed the industry in a year’s time. The company continues to gain from its flagship Impella which saw a solid performance in the United States in recent times. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan also shot up. A raised guidance for fiscal 2019 is indicative of brighter prospects ahead. Considerable expansion in the operating margin buoys optimism. Surging R&D expenses show increasing focus on innovation. Abiomed’s balance sheet remains debt-free. On the flip side, contraction in the company’s gross margin is worrisome. Intense competition in the industry is likely to mar prospects over the long haul. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.”
  • 12/28/2018 – ABIOMED was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/19/2018 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Abiomed outperformed the industry in a year’s time. The company continues to gain from its flagship Impella which saw a solid performance in the United States in recent times. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan also shot up. A raised guidance for fiscal 2019 is indicative of brighter prospects ahead. Considerable expansion in the operating margin buoys optimism. Surging R&D expenses show increasing focus on innovation. Abiomed’s balance sheet remains debt-free. On the flip side, contraction in the company’s gross margin is worrisome. Intense competition in the industry is likely to mar prospects over the long haul. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.”
  • 12/14/2018 – ABIOMED was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $358.00 price target on the stock. According to Zacks, “Abiomed outperformed the industry in a year’s time. The company continues to gain from its flagship Impella which saw a solid performance in the United States in recent times. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan also shot up. A raised guidance for fiscal 2019 is indicative of brighter prospects ahead. Considerable expansion in the operating margin buoys optimism. Surging R&D expenses show increasing focus on innovation. Abiomed’s balance sheet remains debt-free. On the flip side, contraction in the company’s gross margin is worrisome. Intense competition in the industry is likely to mar prospects over the long haul. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.”
  • 12/10/2018 – ABIOMED was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Abiomed outperformed the industry in a year’s time. The company continues to gain from its flagship Impella which saw a solid performance in the United States in recent times. Impella’s patient success stories and increasing global adoptions are major positives. Revenues from Germany and Japan also shot up. A raised guidance for fiscal 2019 is indicative of brighter prospects ahead. Considerable expansion in the operating margin buoys optimism. Surging R&D expenses show increasing focus on innovation. Abiomed’s balance sheet remains debt-free. On the flip side, contraction in the company’s gross margin is worrisome. Intense competition in the industry is likely to mar prospects over the long haul. Abiomed has significant international presence that exposes it to fluctuations in currency exchange rates.”
  • 11/28/2018 – ABIOMED was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/20/2018 – ABIOMED was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/15/2018 – ABIOMED was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

NASDAQ:ABMD opened at $323.80 on Monday. ABIOMED, Inc. has a one year low of $210.36 and a one year high of $459.75. The stock has a market capitalization of $15.15 billion, a P/E ratio of 132.16, a price-to-earnings-growth ratio of 2.75 and a beta of 0.38.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business had revenue of $181.78 million for the quarter, compared to analysts’ expectations of $175.41 million. During the same quarter in the previous year, the firm posted $0.54 earnings per share. The company’s revenue was up 36.9% compared to the same quarter last year. Analysts forecast that ABIOMED, Inc. will post 3.57 EPS for the current year.

Several large investors have recently added to or reduced their stakes in ABMD. NEXT Financial Group Inc acquired a new stake in ABIOMED during the third quarter valued at approximately $115,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in ABIOMED by 160.2% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 320 shares of the medical equipment provider’s stock valued at $144,000 after buying an additional 197 shares in the last quarter. TRUE Private Wealth Advisors acquired a new stake in ABIOMED during the third quarter valued at approximately $162,000. OLD Mutual Customised Solutions Proprietary Ltd. acquired a new stake in ABIOMED during the second quarter valued at approximately $164,000. Finally, Centaurus Financial Inc. acquired a new stake in ABIOMED during the second quarter valued at approximately $205,000. Institutional investors and hedge funds own 87.04% of the company’s stock.

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What is Net Asset Value (NAV)?

Receive News & Ratings for ABIOMED Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply